Isla Mackenzie contributes to undergraduate, postgraduate and multidisciplinary teaching and examining.

My research focuses on improving cardiovascular outcomes and drug safety using a combination of large multicentre randomised clinical trials and pharmacoepidemiological approaches to answer important clinical research questions. I am also interested in clinical trial methodology and improving patient and physician engagement in clinical research. I have a special interest in decentralised clinical trials and I am currently the academic lead of work packages in two IMI projects (Trials@Home and RealHOPE).

Membership of learned societies

•    British and Irish Hypertension Society (Fellow)
•    British Pharmacological Society (Fellow)
•    Caledonian Society of Clinical Pharmacology
•    Digital Health Institute
•    International Society for Pharmacoepidemiology
•    Royal College of Physicians Edinburgh (Fellow)
•    Scottish Heart and Arterial disease Risk Prevention (SHARP) Group
•    Scottish Society of Physicians

Committee appointments and administrative roles

National:

Sports Resolutions Panel of Arbitrators and Mediators. Specialist Member of National Anti-Doping Panel (2018-present)
 
Trustee of Scottish Heart and Arterial disease Risk Prevention (SHARP) Group (2015-)
 
British and Irish Hypertension Society Collaborative Research Working Party (2014-present)
 
Local:
 
Deputy Director of Medicines Monitoring Unit and Hypertension Research Centre
 
Member of Thesis Monitoring Committee, University of Dundee (2013 - present)
 
Member of School of Medicine Equality, Diversity and Inclusion Committee (2016 - 2023)
 
Reviewer of potential REF outputs, Molecular and Clinical Medicine (2017-2023)
 
Member of School of Medicine Research Management Group (2017-2023). Chair (2023-present)

Member of School of Medicine Commercialisation Committee (2021-present)
 
Regularly sit on interview panels for University of Dundee/NHS appointments
 
 
 
Trial Steering Committees:

Standard care versus Celecoxib Outcome Trial (SCOT)
Febuxostat versus Allopurinol Streamlined Trial (FAST)
Prevention And Treatment of Resistant Hypertension With Algorithm based TherapY (PATHWAY) 1, 2 and 3 – University of Cambridge, Cambridge (BHF)
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART)
Treatment in the Morning vs the Evening study (TIME)
Lowering Events in Non-proliferative retinopathy in Scotland (LENS), University of Oxford, Oxford

Blood Donors Studies Steering Committee, University of Cambridge, Cambridge

Co-vice chair ASCEND PLUS steering committee (University of Oxford)